The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.